Literature DB >> 25057953

Breach of tolerance: primary biliary cirrhosis.

Lifeng Wang1, Fu-Sheng Wang1, Christopher Chang2, M Eric Gershwin3.   

Abstract

In primary biliary cirrhosis (PBC), the breach of tolerance that leads to active disease involves a disruption in several layers of control, including central tolerance, peripheral anergy, a "liver tolerance effect," and the action of T regulatory cells and their related cytokines. Each of these control mechanisms plays a role in preventing an immune response against self, but all of them act in concert to generate effective protection against autoimmunity without compromising the ability of the host immune system to mount an effective response to pathogens. At the same time, genetic susceptibility, environmental factors, including infection agents and xenobiotics, play important roles in breach of tolerance in the development of PBC. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25057953     DOI: 10.1055/s-0034-1383729

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  23 in total

Review 1.  IL-35 and Autoimmunity: a Comprehensive Perspective.

Authors:  Jinjung Choi; Patrick S C Leung; Christopher Bowlus; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

Review 2.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Unmet challenges in immune-mediated hepatobiliary diseases.

Authors:  Ulrich Beuers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

4.  Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis.

Authors:  H Tanaka; G-X Yang; T Tomiyama; K Tsuneyama; W Zhang; P S C Leung; R L Coppel; T Joh; S G Nadler; A A Ansari; C Bowlus; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2015-06       Impact factor: 4.330

Review 5.  The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.

Authors:  Ying Sun; Weici Zhang; Baosen Li; Zhengsheng Zou; Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

6.  Successful treatment of murine autoimmune cholangitis by parabiosis: Implications for hematopoietic therapy.

Authors:  Jing-Bo Yang; Yin-Hu Wang; Wei Yang; Fang-Ting Lu; Hong-Di Ma; Zhi-Bin Zhao; Yan-Jie Jia; Wei Tang; Koichi Tsuneyama; William M Ridgway; M Eric Gershwin; Zhe-Xiong Lian
Journal:  J Autoimmun       Date:  2015-10-01       Impact factor: 7.094

Review 7.  New therapies for primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Lisa Perini; Nora Cazzagon; M Eric Gershwin; Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 8.  Primary biliary cholangitis: pathogenesis and therapeutic opportunities.

Authors:  Aliya F Gulamhusein; Gideon M Hirschfield
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-09       Impact factor: 46.802

9.  The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis.

Authors:  Takashi Tomiyama; Guo-Xiang Yang; Ming Zhao; Weici Zhang; Hajime Tanaka; Jing Wang; Patrick Sc Leung; Kazuichi Okazaki; Xiao-Song He; Qianjin Lu; Ross L Coppel; Christopher L Bowlus; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

10.  The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.

Authors:  Fan Yang; Qixia Wang; Zhaoyue Wang; Qi Miao; Xiao Xiao; Ruqi Tang; Xiaoyu Chen; Zhaolian Bian; Haiyan Zhang; Yue Yang; Li Sheng; Jingyuan Fang; Dekai Qiu; Edward L Krawitt; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.